secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001628280-23-025823
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q2 revenue beats; GAAP loss; adjusted EPS down 24%; KidneyCare spinoff named Vantive
--------------------------------------------------------------------------------

- Q2 continuing ops revenue $3.71B, +3% reported (+4% constant currency), above guidance.
- GAAP EPS from continuing ops ($0.39); total GAAP EPS ($0.28); adjusted total EPS $0.66, -24% YoY.
- FY23 adjusted EPS from continuing ops guidance: $2.49-$2.57 (BPS not sold) or $2.54-$2.62 (BPS sold Sept 30).
- Kidney Care spinoff to be named Vantive; Chris Toth named CEO; expected by July 2024.
- Definitive agreement to divest BioPharma Solutions to Advent/Warburg Pincus; closing expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/0001628280-23-025823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828023025823/bax-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-025823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer